Company profile
Axoltis Pharma
Axoltis advances NX210c, under evaluation in a Phase 2 clinical trial in patients with ALS - Results expected Q2 2026
- Industry
- Biotechnology Research
- Employees
- 15
- Headquarters
- Lyon, Auvergne-Rhône-Alpes
- LinkedIn followers
- 4,112
- Office locations
- 1
Axoltis Pharma company summary
Axoltis Pharma is a company in the Biotechnology Research industry, headquartered in Lyon, Auvergne-Rhône-Alpes. On LinkedIn the company has around 15 employees and 4,112 followers. Its listed specialties include neurodegenerative diseases, neurodegeneration, spinal cord injury, peptide, neuroprotection.
What technology does Axoltis Pharma use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Axoltis Pharma
Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today. NX210c is the first targeted - and most advanced - treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026. Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.
Specialties
Where is Axoltis Pharma located?
Axoltis Pharma lists 1 location.
Compare companies similar to Axoltis Pharma
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Axoltis Pharma axoltis.com | Biotechnology Research | 15 | - | Lyon, Auvergne-Rhône-Alpes |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Axoltis Pharma
What does Axoltis Pharma do?
Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today. NX210c is the first targeted - and most advanced - treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026. Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.
How many employees does Axoltis Pharma have?
Axoltis Pharma has around 15 employees on LinkedIn.
Where is Axoltis Pharma headquartered?
Axoltis Pharma is headquartered in Lyon, Auvergne-Rhône-Alpes.
Build a lead list from companies like Axoltis Pharma
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.